FDA's Biggest New Policies Of 2014: Midyear Report

By Jeff Overley (July 28, 2014, 7:08 PM EDT) -- New rules and guidance from the U.S. Food and Drug Administration have made lots of waves with drug and device makers in 2014, sparking debate about future oversight of off-label promotion, social media interactions and the rapidly evolving field of clinical software.

Here are six issues attorneys are watching closely:

Clarity Provided on Twitter Promos

The FDA's long-awaited guidance on promotion via Twitter and other platforms with space limitations was greeted by drugmakers with both acclaim and disappointment, as it simultaneously opened and closed doors for social media advertising.

On the bright side for industry, the FDA clearly stated that tweets...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!